(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.84%.
Lexeo Therapeutics's earnings in 2025 is -$114,172,000.On average, 6 Wall Street analysts forecast LXEO's earnings for 2025 to be -$130,051,124, with the lowest LXEO earnings forecast at -$171,183,848, and the highest LXEO earnings forecast at -$107,462,416. On average, 4 Wall Street analysts forecast LXEO's earnings for 2026 to be -$88,696,994, with the lowest LXEO earnings forecast at -$109,082,452, and the highest LXEO earnings forecast at -$60,481,360.
In 2027, LXEO is forecast to generate -$78,663,568 in earnings, with the lowest earnings forecast at -$111,242,501 and the highest earnings forecast at -$44,821,008.